E-Mail Newsletter (MLL News)

This very different year is coming to an end. We all had to realize, professionally and privately, that plans and goals are only relative. Furthermore, it became clear how centrally "medicine" can influence our daily lives and actions. We as MLL would like to look back and forward and thank you for the trust you have placed in us and for your cooperation.

Advanced molecular genetic testing is gaining ground in the diagnosis of mast cell diseases and hypereosinophilia. In addition to the typical mastocytosis-driver mutation KIT D816 as well as PDGFRA, PDGFRB, FGFR1, and PCM1-JAK2 rearrangements, the MLL uses advanced Next-Generation Sequencing (NGS) mutation analysis to inform the diagnosis and prognostic stratification of these diseases. These NGS gene panels are continuously updated to reflect the latest advances in scientific understanding.

In recent years, research into the underlying pathogenetic mechanisms of hematologic neoplasms has led to remarkable advances in our understanding of these diseases. Cytogenetic and molecular aberrations are the most important factors in determining response to chemotherapy and are increasingly also therapeutic targets. We would first like to provide an overview of novel therapies for AML whose target genes can be sequenced in MLL.

It is now official: As of this year, the MLL Munich Leukemia Laboratory is one of the 50 fastest-growing medium-sized companies in Bavaria. In recent years, the company has been able to increase its sales and the number of its employees at an above-average rate. In recognition of this achievement, MLL was awarded the BAVARIA'S BEST 50 prize by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy (STMWI) and the Deputy Bavarian Prime Minister Hubert Aiwanger.